Answers are grounded in this paper and cite their sources.
Endocrinopathies, particularly thyroid dysfunction and glucose metabolism disorders (GMD), are common in transfusion-dependent β-thalassemia (TDT) patients, but data from Guangxi remain limited. We assessed the prevalence of thyroid dysfunction and GMD and explored associations with anemia and iron metabolism. This cross-sectional study included 440 TDT patients; hematological, iron, thyroid, and glucose indices were measured. Logistic regression was used to identify associated factors. Among 440 patients, 0.2% had hypothyroidism and 22.3% had subclinical hypothyroidism. Among 165 patients assessed for GMD, 5.5% had diabetes mellitus, 2.4% had impaired fasting glucose, and 20.0% had impaired glucose tolerance; 7.9% had both thyroid dysfunction and GMD. Hematocrit was independently associated with thyroid dysfunction (OR 0.93, 95%CI 0.88–0.98). In the 165 glucose-tested patients, red blood cell count (RBC; OR 0.46, 95%CI 0.25–0.87), transferrin (OR 1.21, 95%CI 1.03–1.42), serum ferritin ≥ 2500 ng/mL (OR 3.59, 95%CI 1.28–10.02), and body mass index (BMI; OR 1.33, 95%CI 1.11–1.60) were associated with GMD. Thyroid dysfunction and GMD were prevalent and often coexisted. Hematocrit, RBC, and transferrin may be correlates of these complications. Given the cross-sectional design, these associations should be interpreted cautiously and require prospective validation; nevertheless, monitoring anemia- and iron-related indices may help identify TDT patients requiring further endocrine assessment.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: